



## Nalbuphine Injection – Drug Shortage

- The [drug shortage](#) of Hospira's [nalbuphine](#) injection is ongoing. Nalbuphine has been unavailable for at least 90 days due to a shortage of an active ingredient.
- Nalbuphine is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. It can also be used as a supplement to balanced anesthesia, for preoperative and postoperative analgesia, and for obstetrical analgesia during labor and delivery.

Product Description	NDC #	Availability and Estimated Shortage Duration
Nalbuphine 10 mg/mL; 1 mL glass ampul	00409-1463-01	Next delivery: 6/2020; Estimated recovery: 12/2020
Nalbuphine 20 mg/mL; 1 mL glass ampul	00409-1465-01	Next delivery: 6/2020 Estimated recovery: 12/2020
Nalbuphine 100 mg/10 mL (10 mg/mL); 10 mL multiple dose glass fliptop vial	00409-1464-01	Next delivery and Estimated recovery: 8/2020
Nalbuphine 200 mg/10 mL (20 mg/mL); 10 mL multiple dose glass fliptop vial	00409-1467-01	Next delivery: 11/2020; Estimated recovery: 12/2020



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.